AbbVie’s Q1 Revenue Growth Outpaces Big Pharma Peers
Bouncing back from the pandemic more strongly than its peers, AbbVie sees 40% growth for Botox and Juvederm, a good launch for Ubrelvy and continued strength from its mainstays.
You may also be interested in...
With an FDA approval decision for preventing episodic migraines expected during Q3, atogepant would add an oral CGRP antagonist to classmate Ubrelvy for acute attacks and Botox for prevention of chronic episodes.
Keeping Track: Cloudy Horizon For Teplizumab, Roxadustat; Nuplazid Stumbles Over Subgroups; CAR-T Submissions From Gilead, J&J
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
After Pfizer saw increased risks in a surveillance study of Xeljanz, three other products have also seen their user fee dates pushed back; if FDA were to convene an expert panel, it could lead to more consistent labeling across the class, as requested in a recent citizen petition.